Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has issued an update.
Shin Nippon Biomedical Laboratories, Ltd. has revised its consolidated earnings forecast for the fiscal year ending March 31, 2025, citing better-than-expected sales and orders in its nonclinical CRO business. The forecast revisions include an increase in revenue and profits, attributed to lower operational costs at its US subsidiary and higher profit shares from equity method investments. This positive outlook is based on a stable exchange rate of 145.00 yen to the US dollar.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the nonclinical contract research organization (CRO) industry. The company primarily focuses on providing preclinical research services, with a significant emphasis on its nonclinical CRO business.
YTD Price Performance: -0.42%
Average Trading Volume: 317,328
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: Yen69.15B
For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.
